SAN DIEGO, March 12, 2012 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc.

Young infants and toddlers with sickle cell anemia who received the drug hydroxyurea were no more likely to have cellular genetic damage than those who received a placebo or inactive medicine.

Research assessing the safety and efficacy of hydroxyurea therapy in pediatric patients with sickle cell disease (SCD) and the use of pre-operative transfusions for patients with SCD who undergo low- and moderate-risk elective surgery will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

SAN DIEGO, Dec.

A University of Michigan Health System laboratory study reveals a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease.